Deals channel feed – Endpoints News

Deals channel feed

Siga nabs $10.7M from the US government in deal for its monkeypox antiviral

3 years ago

Almirall partners up with Simcere in potential $500M+ deal — with plans to take IL-2 candidate global

3 years ago

As lead drug flopped and AbbVie collab dissolved, cancer biotech resorts to buying rare disease company

3 years ago

Novo Nordisk joins Novartis, Roche in NLRP3 arena, betting $70M cash on NASH, cardiometabolic uses

3 years ago

SFJ plays hardball, demands rights to PhaseBio's lead candidate

3 years ago

Emergent closes on buying smallpox drug Tembexa from Chimerix with a $238M payment

3 years ago

ArsenalBio lands $70M cash deal with cancer giant Genentech to develop cell therapy

3 years ago

Sanofi turns to a Jennifer Doudna gene editing upstart for next-gen NK cell alliance

3 years ago

Seagen tees up with Dutch I/O outfit, engineers $700M deal for EGFR asset

3 years ago

Armed with cash, Belgian iPSC player makes a play for Celyad’s cell therapy manufacturing site

3 years ago

Inventiva signs over China NASH rights to Sino Biopharm in possible $300M+ deal

3 years ago

Lending a hand to a biotech in trouble, GSK drops $75M cash to add late-stage antibiotic to portfolio

3 years ago

Servier cuts off collaboration agreement with Allogene on CD19 products, sending shares sputtering

3 years ago

FTC chair Lina Khan to Senate: Big Pharma M&A is still a priority target

3 years ago

Merck KGaA teams up with Italian oncology group in PARP1 development deal

3 years ago

Carisma's CAR-M steals spotlight among 42 bidders to reverse merge with Sesen Bio

3 years ago

Novo Nordisk Foundation issues $200M grant to apply quantum computing to life sciences, drug discovery

3 years ago

Swiss pharma Basilea sheds yet another oncology program as anti-infectives pivot plows forward

3 years ago

One SPAC's journey to find a partner, and its race against the clock, shows toughness of bear market

3 years ago

Renovacor ships its cardiac gene therapy to Rocket in $53M all-stock deal

3 years ago

Theravance declares independence from GSK, crafts $250M plan to buy back its own shares

3 years ago

After selling failed NASH drug to Ipsen, French startup nabs a liver disease player in small buyout

3 years ago

AmerisourceBergen throws down nearly $1.3B cash for German life sciences company

3 years ago

Novo Nordisk execs had only one drug on their mind when they came calling at Forma. Here's the inside story of their $1.1B buyout

3 years ago

First page Previous page 51 52 535455 56 57 Next page Last page